Leo Wealth LLC Makes New $1.98 Million Investment in Illumina, Inc. $ILMN

Leo Wealth LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, Holdings Channel.com reports. The institutional investor purchased 7,244 shares of the life sciences company’s stock, valued at approximately $1,981,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hilton Head Capital Partners LLC acquired a new stake in shares of Illumina in the third quarter valued at about $82,000. Leeward Financial Partners LLC bought a new position in shares of Illumina in the third quarter worth about $4,410,000. Sigma Planning Corp increased its stake in shares of Illumina by 91.1% in the third quarter. Sigma Planning Corp now owns 6,980 shares of the life sciences company’s stock worth $1,910,000 after purchasing an additional 3,327 shares during the period. Signaturefd LLC lifted its position in shares of Illumina by 8.4% during the 3rd quarter. Signaturefd LLC now owns 5,897 shares of the life sciences company’s stock worth $1,614,000 after purchasing an additional 457 shares during the last quarter. Finally, Evergreen Capital Management LLC lifted its position in shares of Illumina by 0.5% during the 3rd quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company’s stock worth $2,593,000 after purchasing an additional 50 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Leerink Partners raised their target price on Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $135.00 to $260.00 in a research report on Wednesday, September 9th. Guggenheim upped their price target on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Finally, Piper Sandler increased their price objective on Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, September 28th. Ten analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $234.41.

Illumina Stock Up 0.6%

NASDAQ ILMN opened at $271.04 on Tuesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm has a 50-day simple moving average of $241.80 and a 200 day simple moving average of $173.01. Illumina, Inc. has a twelve month low of $94.00 and a twelve month high of $309.35. The stock has a market cap of $40.93 billion, a PE ratio of 50.57, a PEG ratio of 3.82 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the business earned $1.19 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Buying and Selling

In other news, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the sale, the director owned 770,350 shares in the company, valued at approximately $168,244,440. This represents a 13.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,061,850 shares of company stock valued at $436,479,102 in the last quarter. Corporate insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.